In LS, particularly among individuals with MLH1, MSH2, or EPCAM mutations, close monitoring for MM, BCC, SCC, and precancerous lesions—beyond rare sebaceous manifestations—may be warranted starting at age 18. Here, MLH1 is linked to Miyoshi myopathy.